SELF-ADMINISTERED etripamil, an intranasal calcium channel blocker, significantly reduces emergency department (ED) visits ...

Milestone Pharmaceuticals' stock fell 50% after the FDA's CRL for CMC issues, but the drug Etripamil has shown efficacy and ...

USA: A recent study published in JAMA Cardiology revealed that self-administered etripamil was almost twice as effective as ...

The nasal spray is under development to treat episodes of abnormal heart rhythm associated with Paroxysmal supraventricular tachycardia (PSVT). The FDA highlighted two key Chemistry, Manufacturing ...

“We are deeply disappointed by the CRL but remain committed to the potential of CARDAMYST as a novel treatment option that can help patients with PSVT. Our team is evaluating the feedback ...

Milestone Pharmaceuticals faces an FDA setback for its PSVT nasal spray. The company coordinates with regulatory authorities to resolve CRL issues. TD Cowen downgraded Milestone Pharmaceuticals ...

Paroxysmal supraventricular tachycardia (PSVT) and paroxysmal atrial fibrillation/flutter (PAF): 50mg every 12 hours; increase in increments of 50mg twice daily every 4 days until efficacy is ...